Core Insights - CorMedix Therapeutics will host an in-person and virtual analyst day on February 10, 2026, to discuss its portfolio and pipeline, highlighting key growth drivers and upcoming milestones [1][2] Company Overview - CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [4] - The company is commercializing DefenCath® for the prevention of catheter-related bloodstream infections and has a portfolio of anti-infective products following its acquisition of Melinta Therapeutics [4] Product Pipeline - CorMedix's REZZAYO® program is in Phase III for the prophylaxis of fungal infections, while DefenCath® is in Phase III for reducing CLABSI in adult patients receiving Total Parenteral Nutrition [2][5] - Topline results for the Phase III study of REZZAYO are expected in Q2 2026 [5] Event Details - The analyst day will feature key opinion leaders and senior management discussing market dynamics and unmet medical needs [2] - A live question-and-answer session will follow the presentations, with in-person attendance limited to analysts and institutional investors [3]